Current treatment strategies in follicular lymphomas
|
|
- Bethany Flynn
- 6 years ago
- Views:
Transcription
1 17 (Supplement 10): x155 x159, 2006 doi: /annonc/mdl253 Current treatment strategies in follicular lymphomas W. Hiddemann & M. Unterhalt Department of Internal Medicine III, University of Munich, Munich, Germany introduction and background Follicular lymphoma (FL) is the second most frequent lymphoma subtype worldwide [1]. Its incidence is rapidly increasing in Western countries and has nearly doubled within the last three decades. In less than 15 20% of patients FL is detected at the early stages I or II. In these patients radiotherapy is the treatment of choice and is applied as extended or involved field irradiation that results in long-term disease-free survival (DFS) and probable cure in approximately 45 80% of patients. In the majority of patients, however, the disease is diagnosed at an advanced stage III or IV and cannot be cured by conventional therapeutic approaches. Hence, anti-lymphoma therapy is usually withheld for a watch and wait period until the disease becomes symptomatic. In this situation a broad spectrum of therapeutic options is available ranging from single agent to combination chemotherapy. In spite of numerous efforts and the exploration of different regimens, chemotherapy has had no major impact on survival and the prognosis of FL has literally remained unchanged over the last decades with a median survival time of 8 10 years [2, 3]. Recently, new treatment modalities have been developed which justify the hope for improving the long-term outcome of patients suffering from FL. These include in particular myeloablative therapy followed by autologous stem cell transplantation (ASCT) and monoclonal antibodies with an inherent anti-lymphoma activity or as carriers for radioisotopes or immunotoxins. myeloablative therapy with subsequent autologous stem cell transplanation (ASCT) After the feasibility and potential efficacy of ASCT was demonstrated in patients with relapsed disease [4 8] ASCT was investigated as consolidation therapy in first remission of advanced stage FL and showed promising long-term results. Most recently, the data of three cooperative group, multicenter randomized trials have become available. They consistently show a significant prolongation of response duration while data on overall survival are different (Table 1). In the first study that was published by the German Low Grade Lymphoma Study Group (GLSG) the median observation time is still too short to judge the impact of ASCT on overall survival [9]. In the study by the French GOELAMS (Groupe Ouest Est des Leucémies et des Autres Maladies du Sang) study group a high incidence of secondary malignancies was observed in the ASCT arm resulting in a similar survival duration in both treatment arms [10]. In contrast, the trial of the GELA (Groupe D Etudes des Lymphomes De l Adulte), revealed a significantly longer overall survival for the transplant arm [11]. One of the major reasons for these differences appears to be secondary malignancies and in particular secondary acute myeloid leukemias (AML) or myelodysplastic syndromes (MDS) after ASCT. Several retrospective non-randomized analyses reported an incidence of 1% up to 12% [12, 13]. More valuable results can be derived from the afore-mentioned three prospective randomized studies. They show substantial differences in the risk of secondary AML and MDS being 0% in the GELA study, 8.5% in the GOELAMS study and 3.8% in the GLSG trial. A subgroup analysis of the GLSG study suggests that the risk of secondary MDS or AML may be associated with the type of initial chemotherapy rather than with the conditioning procedure. Hence, after cytoreduction with MCP (Mitoxantrone, Chlorambucil, Predisone) the risk was 5.1 % at 5 years as compared to only 1% after CHOP [14]. Hence, myeloablative radiochemotherapy followed by ASCT is an effective treatment option for young patients (<65 years) with advanced stage FL lymphoma, which improves response duration and potentially also overall survival. Especially after a CHOP-like induction therapy, the increase of secondary hematologic neoplasias is moderate and acceptable and should not preclude the offer of such treatment to young patients with a high or intermediate risk profile. As new approaches such as the combination of chemotherapy with monoclonal antibodies and particularly with Rituximab are implemented in multi-modal approaches the role of ASCT may have to be redefined. anti-lymphoma antibodies with inherent anti-lymphoma activity The only currently available anti-lymphoma antibody with a widely proven activity in FL is the monoclonal antibody (mab) Rituximab. Several phase II clinical trials demonstrated a significant single agent activity of Rituximab given every week at a dose of 375 mg/m 2 /d in pretreated as well as in previously untreated patients with FL although response duration was relatively short (12 17 months) [15 19]. Response duration ª 2006 European Society for Medical Oncology
2 could be prolonged by continued application of Rituximab in remission as a maintenance therapy [20, 21]. Based on these promising results Rituximab was combined with chemotherapy and a first phase II trial on the combination of Rituximab with CHOP showed responses in all evaluable patients with a complete remission (CR) rate of 63 % and a median PFS of 82 months [22]. The first prospective randomized comparison of the combination of Rituximab plus chemotherapy versus chemotherapy alone was carried out by the GLSG in patients with relapsed FL and mantle cell lymphomas (MCL). In this trial Rituximab was added to the FCM (Fludarabine, Cyclophosphamide, Mitoxantrone) combination which was randomly compared with FCM alone. R-FCM revealed a significantly higher remission rate, a significantly longer PFS and particularly overall survival for both lymphoma subtypes [23]. Most recently the results of four prospective randomized phase III studies investigating Rituximab plus chemotherapy versus chemotherapy alone have become available (Table 2) [24 27]. They consistently show that the addition of Rituximab to different chemotherapeutic regimens results in a significant increase in response rates, time to treatment failure and response duration. In the study by the GLSG comparing Rituximab plus CHOP (R-CHOP) or CHOP alone even overall survival was prolonged [24]. A different strategy was applied by the Eastern Cooperative Oncology Group (ECOG). In a recently completed randomized phase III study remission induction by CVP was followed by Rituximab maintenance over 2 years or observation only. By Rituximab maintenance a 2.7 year longer PFS was achieved (P =) [28]. Two recently reported trials investigated the efficacy of Rituximab maintenance after R-chemotherapy in patients with relapsed FL. The first study by the GLSG was based on the previously mentioned R-FCM regimen [29] while the EORTC/ Intergroup study used R-CHOP for salvage treatment [30]. In both trials a significant prolongation of response duration was observed. In conclusion, all available randomized studies consistently show that Rituximab has a significantly beneficial effect in patients with advanced stage follicular lymphoma either when given in addition to initial chemotherapy or as maintenance after cytoreductive therapy with and without Rituximab or by prolonged application as a single agent. It is therefore no longer the question whether Rituximab should be applied for first-line Table 1. Results of prospective randomized trials on myeloablative therapy with subsequent autologous stem cell transplantation (ASCT) in first remission of follicular lymphoma Trial [Reference] Induction Consolidation (number of patients) Event-free survival Overall survival Phase III Lenz et al. (GLSG) [9] CHOP/MCP (4 6 cycles) CHOP/MCP (4 6 cycles) (n = 153) IFN-maintenance (n = 154) 64.7% versus 33.3%* (P <.0001) Not yet available Phase III Deconinck et al. (GOELAMS) [10] Phase III Sebban et al. (GELA) [11] VCAP (2 3 cycles) CHVP/IFN-a (6 cycles) CHOP (4 cycles) CHVP/IFN-a (6 cycles) (n = 86) CHVP plus IFN-a (n = 80) (n = 192) CHVP plus IFN-a (n = 209) 60% versus 48% + (P <0.050) 45% versus 36% (P = 0.5) Median not reached in both treatment arms No significant difference 86% versus 74% (P = 0.05) (7-year OS) PFS, progression-free survival; EFS, event-free survivial; OS, overall survival. TBI, total body irradiation; Cyclo, cyclophosphamide. 5-year PFS; + 5-year EFS; 7-year EFS. Table 2. Rituximab plus chemotherapy in first-line therapy of advanced stage follicular lymphoma Author [Reference] Regimen (number of patients) P-value Hiddemann et al. [24] CHOP (205) R-CHOP (223) Response rate 90% 96% P = Median time to treatment failure 31 months Not reached P < Marcus et al. [25] CVP (159) R-CVP (162) Response rate 57% 81% P < Median time to treatment failure 7 months 27 months P < Herold et al. [26] MCP (96) R-MCP (105) Response rate 75% 92% P <0.001 Median event-free survival 19 months Not reached P < Salles et al. [27] CHVP/IFN-a (175) R-CHVP/IFN-a (184) Response rate (CR/Cru) 85% (49%) 94% (76%) P < Median event-free survival Not reached Not reached x156 Hiddemann & Unterhalt Volume 17 Supplement 10 September 2006
3 therapy of advanced stage follicular lymphomas but rather how. Although further studies are needed to address this question in greater detail it may be speculated that the different ways of application might not be used competitively but rather complementary and might be appropriate for different patient populations as defined by age, performance status, international prognostic index (IPI) or the recently introduced IPI for follicular lymphoma (FLIPI) [31]. anti-lymphoma antibodies as carriers for radio-isotopes (Radio-Immunotherapy) Because of the inherent high radiosensitivity of FL and the expression of potential target antigens on the cell surface radioimmunotherapy (RIT) represents an especially promising concept in this disease. At present, the majority of radioimmunoconjugates target the CD20 antigen which is expressed on most B cell lymphomas and is neither shed nor internalized thus representing an appealing target for RIT. Radiolysis is induced in both the targeted cells and adjacent lymphoma cells due to the radiation crossfire effect, which may be especially advantageous for treating bulky, poorly vascularized tumors and those with heterogeneous antigen expression. So far, most clinical experience has been gained with two different radio-immunoconjugates, the Yttrium-90 ( 90 Y)- labeled murine antibody Ibritumomab (ZevalinÒ) and the Iodine-131 ( 131 I)-labeled antibody Tositumomab (BexxarÒ). 90 Y-Ibritumomab is a pure b-emitter of high energy with a short half-life of 64 h and is therefore suitable for outpatient treatment. 131 I-Tositumomab delivers both b and c-irradiation with a half-life of 8 days, therefore shielding of persons in contact is necessary (Table 3). Both constructs may be applied in a non-myeloablative as well as myeloablative dosage. In the non-myeloablative approach both conjugates demonstrated comparable activity with response rates of 60 80% and complete response (CR)/complete remission uncertain (Cru)-rates between 15 44% [32]. Most recently Kaminski et al. reported that 131 I-tositumomab induced high response rates of 95% with 75% CR in first-line therapy of FL [33]. Although these results were obtained in patients with a very favorable prognostic profile the fact that more than half of the patients remained in a continuous CR after a minimum follow-up of more than 4 years strongly supports further testing of this approach in prospective randomized studies. Myeloablative radio-immunotherapy with subsequent re-infusion of autologous peripheral stem cells has been successfully used in patients with refractory or relapsed FL. Table 3. Characteristics of the radioisotopes 90 Yttrium and 131 Iodine 90 Yttrium 131 Iodine Source of Radiation beta beta and gamma Energy (MeV) / 0.61 Depth of activity (mm) Half time (h) Application Out-patient In-patient (radioprotection) A single myeloablative dose of 131 I-Tositumomab achieved an overall response rate of 93% with a CR/CRu rate of 85% and an estimated 5-year PFS and overall survival (OS) of 48% and 67%, respectively, in comparison to 29% and 53% after high-dose chemotherapy [34]. Besides single agent RIT this approach may also be combined with conventional chemotherapy as consolidation in remission. Applying such a combination Press et al. reported response rates of 67% CR/CRu and 23% partial response (PR) in a phase II study with 131 I-Tositumomab in previously untreated FL patients [35]. After a median follow-up of 2.3 years, the estimated 2-year PFS was 81% with a 2-year OS of 97%. Hence, RIT represents a highly attractive and promising approach for the treatment of FL. However, comparison with other treatment modalities in way of prospective randomized studies is warranted to define the definite role and the way and timing of RIT in the overall strategy of FL therapy. new agents and therapeutic approaches biologic agents FL is characterized by a translocation between the chromosomes 14 and 18 that brings the bcl-2 gene under the transcriptional control of the immunoglobulin heavy chain promoter. Resulting overexpression of the Bcl-2 protein can be detected in the vast majority of FL and has been associated with cellular resistance to apoptosis and chemotherapy [36]. Specific inhibition of gene expression can be achieved by chemically modified single-strand DNA molecules with a nucleotide sequence complementary to that of their target mrna. Oblimersen (formely known as G3139) is an 18-mer phosphorothioate oligonucleotide targeting the first six codons of the bcl-2 mrna open reading frame. A dose escalating study of oblimersen administered as a 14-day subcutaneous infusion in 21 patients with advanced, relapsed Bcl-2 positive non-hodgkin s lymphoma (NHL) including nine cases of FL demonstrated feasibility and suggested clinical activity [37]. Based on promising in vitro data ongoing studies currently explore the combination of oblimersen with Rituximab [38]. The ubiquitin-proteasome pathway is essential for maintaining intracellular protein homeostasis, thus representing a valid target in the treatment of malignant disease. At the center of this degenerative pathway is the 26S proteasome, an ATPdependent multicatalytic protease. Various oncogenes and regulatory proteins for cell cycle progression and apoptosis are processed by this pathway including p53, p21, p27, nuclear factor kappa B (NFjB) and Bcl-2 [39]. Bortezomib is a potent, selective, reversible inhibitor of the 26S proteasome and demonstrated clinical activity in relapsed multiple myeloma. Encouraging data were also observed in patients with other lymphoproliferative malignancies, including FL and MCL [40, 41]. Preliminary data from a phase II trial indicate that responses may continue to occur until several months after the end of treatment [42]. Bortezomib is currently explored in several phase II studies that also explore its combination with other cytostatic agents such as liposomal doxorubicin [43]. Volume 17 Supplement 10 September 2006 doi: /annonc/mdl253 x157
4 Another interesting agent is the orally available dipeptidyl peptidase inhibitor (PT-100, Talabostat), which acts via novel immune mechanisms by up-regulated gene expression of certain cytokines within the hematopoetic tissue [44, 45]. adoptive immunotherapy Active immunotherapy in FL aims for generation of a humoral and/or cellular immune response of the host against highly specific lymphoma antigens. The hypervariable region (idiotype, Id) is unique to each lymphoproliferative clone, representing an attractive target for vaccination strategies. A recent retrospective analysis of 136 patients with FL who received Id vaccination following chemotherapy demonstrated anti-id responses in 47% and significantly prolonged PFS (8.21 versus 3.38 years, P = 0.018) in those with detectable idiotype-specific humoral immune response [46]. Efficacy of this approach might be further improved by adding granulocyte macrophage stimulating factor (GM-CSF) for enhanced induction of T-cell response [47]. Probably the optimal setting for vaccination strategies is the minimal residual disease (MRD) state with adequate recovery of immune effector mechanisms after chemotherapy. Improved manufacturing methods are being developed to make these individualized vaccines feasible for more widespread use. In the light of constantly increasing clinical experience with novel therapeutic agents there is justified optimism to shift treatment towards pathogenesis-oriented and lymphomaspecific approaches. Whether this will translate into impact on natural history of FL remains to be awaited. Obviously further comparative clinical trials are desperately needed, as clinicians will have to face the challenge of how to best integrate these exciting new options into existing established treatment algorithms. references 1. The Non-Hodgkin s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-hodgkin s lymphoma. Blood 1997; 89: Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-hodgkin s lymphomas. N Engl J Med 1984; 311: Gallagher CJ, Gregory WM, Jones AE et al. Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol 1986; 4: Freedman AS, Neuberg D, Mauch P et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-hodgkin s lymphoma. J Clin Oncol 1997; 15: Apostolidis J, Gupta RK, Grenzelias D et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: longterm clinical and molecular follow-up. J Clin Oncol 2000; 18: Van Besien K, Loberiza FR, Bajorunaite R et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003; 102: Schouten HC, Qian W, Kvaloy S et al. High-dose therapy improves progressionfree survival and survival in relapsed follicular non-hodgkin s lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: Deconinck E, Foussard C, Milpied N et al. High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Blood 2005; 105: Sebban C, Belanger C, Brousse N et al. Comparison of CHVP + Interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden Follicular Lymphoma: Results of the randomized GELF94 trial (G.E.L.A. Study Group). Blood 2003, 102: 354a. 12. Micallef IN, Lillington DM, Apostolidis J et al. Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies. J Clin Oncol 2000; 18: Howe R, Micallef IN, Inwards DJ et al. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma. Bone Marrow Transplant 2003; 32: Lenz G, Dreyling M, Schiegnitz E et al. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 2004; 22: Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin s lymphoma. Blood 1997; 90: McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-cd20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: Feuring-Buske M, Kneba M, Unterhalt M et al. IDEC-C2B8 (Rituximab) anti- CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-ii study of the German Low-Grade Lymphoma Study Group. Ann Hematol 2000; 79: Hainsworth JD, Litchy S, Burris HA et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin s lymphoma. J Clin Oncol 2002; 20: Colombat P, Salles G, Brousse N et al. Rituximab (anti-cd20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: Ghielmini M, Schmitz SF, Cogliatti SB et al. Prolonged treatment with Rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule. Blood 2004; 103: Hainswoth J, Sitchy S, Greco FA. Scheduled Rituximab maintenance therapy versus Rituximab retreatment at progression in patients with indolent non-hodgkin s lymphoma (NHL) responding to single-agent Rituximab: a randomized trial of the Minnie Pearl Cancer Research Network. Blood 2003; 102: 69a. 22. Czuczman MS, Weaver R, Alkuzweny B et al. Prolonged clinical and molecular remission in patients with low-grade or follicular Non-Hodgkin s lymphoma treated with Rituximab plus CHOP chemotherapy: 9 year follow-up. J Clin Oncol 2004; 22: Forstpointner R, Dreyling M, Repp R et al. The addition of Rituximab to a combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantel cell Lymphomas results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004; 104: Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with Rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome for patients with advanced stage follicular lymphoma compared with therapy with CHOP alone: - Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2005; 106: x158 Hiddemann & Unterhalt Volume 17 Supplement 10 September 2006
5 25. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus Rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: Herold M, Pasold R, Srock S et al. Results of a prospective randomised open label phase III study comparing Rituximab plus Mitoxantrone, Chlorambucil, Prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-hodgkin s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 2004; 104: 584a. 27. Salles G, Foussard C, Nicolas M et al. Rituximab added to aifn+chvp improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 2004; 104: 160a. 28. Hochster HS, Weller E, Ryan T et al. Results of E 1496: A phase III trial of CVP with or without maintenance Rituximab in advanced indolent lymphoma (NHL). Proc Am Soc Clin Oncol 2004; 23: Hiddemann W, Forstpointner R, Dreyling M et al. Rituximab maintenance following a Rituximab containing chemotherapy significantly prolongs the duration of response in patients with relapsed follicular and mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 2005; 23: Van Oers MHJ, Van Glabbeke Mm, Teodorovic I et al. Chimeric anti-cd 20 monoclonal antibody (Rituximab, Mabthera) in remission induction and maintenance treatment of relapsed/resistant follicular non-hodgkin s lymphoma: A phase III randomized intergroup clinical trial. Proc Am Soc Hematol 2005; 104: 169a. 31. Solal Celigny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood 2004; 104: Kaminski MS, Estes J, Zasadny KR et al. Radioimmunotherapy with iodine (131)I Tositumomab for relapsed or refractory B-cell non-hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: Kaminski MS, Tuck M, Estes J et al. 131 I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: Gopal AK, Gooley TA, Maloney DG et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: Press OW, Unger JM, Braziel RM et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicularnon- Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003; 102: Gascoyne RD, Krajewska M, Krajewska S et al. Prognostic significance of Bax protein expression in diffuse aggressive non-hodgkin s lymphoma. Blood 1997; 90: Waters JS, Webb A, Cunningham D et al. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin s lymphoma. J Clin Oncol 2000; 18: Ramanarayanan J, Hernandez-Ilizaliturri FJ, Czuczman M. In vivo downregulation of bcl-2 by G3139 (G) enhances Rituximab Ò anti-tumor activity: Effect of sequential versus concurrent G3139 administration on survival in a lymphomabearing SCID mouse model. Blood 2004; 104: 392a. 39. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: Strauss SJ, Maharaj L, Stec J et al. Phase II clinical study of Bortezomib (VELCADEÒ) in patients (pts) with relapsed/refractory non-hodgkin s lymphoma (NHL) and Hodgkin s disease (HD). Blood 2004; 104: 389a. 42. O Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-hodgkin s lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: Orlowski RZ, Voorhees PM, Garcia RA et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: Adams S, Miller GT, Jesson MI et al. PT-100, a small molecule dipeptidyl peptidase inhibitor, has potent antitumor effects and augments antibodymediated cytotoxicity via a novel immune mechanism. Cancer Res 2004; 64: Al-Katib A, Hurd DD, Raju R et al. Phase I study of Talabostat and Rituximab in patients with indolent non-hodgkin s lymphoma with primary resistance to or progression following Rituximab. Blood 2004; 104: 394a. 46. Weng WK, Czerwinski D, Timmerman J et al. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol 2004; 22: Bendandi M, Gocke CD, Kobrin CD et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nature Med 1999; 5: Volume 17 Supplement 10 September 2006 doi: /annonc/mdl253 x159
Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma
Annals of Oncology 16 (Supplement 2): ii99 ii104, 2005 doi:10.1093/annonc/mdi724 Advances in molecular biology diagnostic and treatment of B-cell malignancies: indolent B-cell lymphoma M. Dreyling, C.
More informationUpdate: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationNon Transplant-Related Treatment Options in Follicular Lymphoma
Biology of Blood and Marrow Transplantation 12:53-58 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0111$32.00/0 doi:10.1016/j.bbmt.2005.10.003 Non Transplant-Related
More informationWhat Is the Role of Maintenance Rituximab in Follicular NHL?
Review Article [1] January 01, 2008 By David G. Maloney, MD, PhD [2] Recent trials have demonstrated improvements in progression-free and overall survival with the inclusion of the chimeric anti-cd20 monoclonal
More informationAdvances in the management of follicular lymphoma
Hematology Meeting Reports 2007; 1(5):43 51 Advances in the management of follicular lymphoma Michele Ghielmini Oncology Institute of Southern Switzerland, Oncologia medica, Bellinzona, Switzerland Corresponding
More informationOutcomes of Treatment in Slovene Follicular Lymphoma Patients
Original Study Outcomes of Treatment in Slovene Follicular Lymphoma Patients Tanja Juznic Setina, Simona Borstnar, Barbara Jezersek Novakovic Abstract The treatment outcomes of follicular lymphoma (FL)
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationOpen questions in the treatment of Follicular Lymphoma. Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland
Open questions in the treatment of Follicular Lymphoma Prof. Michele Ghielmini Head Medical Oncology Dept Oncology Institute of Southern Switzerland Survival of major lymphoma subtypes at IOSI 1.00 cause-specific
More informationThe role of stem cell transplant for lymphoma in 2017
DOI: 10.1002/hon.2396 SUPPLEMENT ARTICLE The role of stem cell transplant for in 2017 John G. Gribben Barts Cancer Institute, Queen Mary University of London, London, UK Correspondence John G. Gribben,
More informationIs there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes
Is there a role of HDT ASCT as consolidation therapy for first relapse follicular lymphoma in the post Rituximab era? Yes Bertrand Coiffier Service d Hématologie Hospices Civils de Lyon Equipe «Pathologie
More informationLong-Term Survival after Autologous Bone Marrow Transplantation for Follicular Lymphoma in First Remission
Biology of Blood and Marrow Transplantation 13:1057-1065 (2007) 2007 American Society for Blood and Marrow Transplantation 1083-8791/07/1309-0001$32.00/0 doi:10.1016/j.bbmt.2007.05.012 Long-Term Survival
More informationThe Role of Hematopoietic Cell Transplantation for Follicular Non-Hodgkin s Lymphoma
Biology of Blood and Marrow Transplantation 12:59-65 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0112$32.00/0 doi:10.1016/j.bbmt.2005.10.006 The Role of Hematopoietic
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationORIGINAL ARTICLE. Suresh Advani 1, Shubhadeep Sinha 2, Pankaj Thakur 3, Neetu Naidu 3, Sreenivas Chary 3, Ghanshyam Biswas 4, Vamsi Krishna Bandi 5
58 ORIGINAL ARTICLE Efficacy, Safety and Immunogenecitystudy of Intravenous Infusion of Rituximab (Hetero) and Reference Medicinal Product (Rituximab, Roche) in Indian Patients of Follicular Lymphoma Preliminary
More informationIs there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France
COSTEM Berlin September 8-11 211. Is there still a role for autotransplant with follicular lymphoma in the rituximab era. Pr. Christian Gisselbrecht Hôpital Saint Louis Paris, France World Health Organization
More informationTRANSPARENCY COMMITTEE OPINION. 8 November 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 8 November 2006 MABTHERA 100 mg, concentrate for solution for infusion (CIP 560 600-3) Pack of 2 MABTHERA 500 mg,
More informationBrad S Kahl, MD. Tracks 1-21
I N T E R V I E W Brad S Kahl, MD Dr Kahl is Associate Professor and Director of the Lymphoma Service at the University of Wisconsin School of Medicine and Public Health and Associate Director for Clinical
More informationclinical practice guidelines
Annals of Oncology 22 (Supplement 6): vi59 vi63, 2011 doi:10.1093/annonc/mdr388 Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationTositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1
Generic (Trade Name): Manufacturer: Tositumomab and iodine I 131 tositumomab (Bexxar ) Corixa Corporation; marketed by GlaxoSmithKline 1 NO. 64 OCTOBER 2005 Indication: Current Regulatory Status: In the
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationThe role of rituximab for maintenance therapy in
COUNTERPOINTS Current Controversies in Hematology and Oncology Counterpoints Is Maintenance Therapy Necessary in Low-Grade Lymphoma? Maintenance therapy with rituximab has been shown to prolong progression-free
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationAddress correspondence to: Brad S. Kahl, MD 1111 Highland Avenue, 4059 WIMR Madison, WI
Yttrium 90-Ibritumomab Tiuxetan Plus Rituximab Maintenance as Initial Therapy for Patients With High-Tumor-Burden Follicular Lymphoma: A Wisconsin Oncology Network Study Saurabh Rajguru, MD, Thorhildur
More informationThe case for maintenance rituximab in FL
New-York, October 23 rd 2015 The case for maintenance rituximab in FL Pr. Gilles SALLES For FL patients, progression-free survival still needs to be improved Median R-CHVP-I 66 months P
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationUpdates in the Treatment of Non-Hodgkin Lymphoma: ASH Topics
Updates in the Treatment of Non-Hodgkin Lymphoma: ASH 2008 Joseph Tuscano, M.D. UC Davis Cancer Center 1 Topics Mantle Cell Lymphoma What is the standard of care for younger patients? (abstracts 581, 769,
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 July 2012 MABTHERA 100 mg, concentrate for solution for infusion B/2 (CIP code: 560 600-3) MABTHERA 500 mg, concentrate
More informationAnti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma
Acta Histochem. Cytochem. 35 (4): 275 279, 2002 Review Anti-CD20 Monoclonal Antibody as a New Treatment Modality for B-Cell Lymphoma Tomomitsu Hotta 1 1 Division of Hematology and Oncology, Department
More informationRituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting
1 Recruiting A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Conditions: Waldenstrom's ; Waldenstrom Macroglobulinaemia Intervention: Biological: Ofatumumab Sponsor: GlaxoSmithKline Number
More informationExpanding the Horizons )N 3UPPORTIVE #ARE /NCOLOGY. Communiqué from ICML 2008
C A n a d i a n V i s i o n f o r O n c o l o g y )N 3UPPORTIVE #ARE /NCOLOGY Number 10 July 2008 PUBLICATIONS MAIL AGREEMENT NO. 41495516 RETURN UNDELIVERABLE CANADIAN ADDRESSES TO NEW EVIDENCE 4133 DUNDAS
More informationModel-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma
Model-based optimization of rituximab dosing regimen in follicular non-hodgkin lymphoma D. Ternant, E. Hénin, G. Cartron, M. Tod, G. Paintaud, P. Girard Introduction Objectives Introduction Rituximab in
More informationGLSG/OSHO Study Group. Supported by Deutsche Krebshilfe
GLSG/OSHO Study Group Supported by Deutsche Krebshilfe founded in 1985 Comparison of Two Consecutive Study Generations of the GLSG Overall Survival Follicular Lymphomas Questions for the Next Steps of
More informationAntibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma
Antibody-Based Immunotherapeutic Agents for Treatment of Non-Hodgkin Lymphoma Steven I. Park, MD, 1* and Kristy L. Richards, PhD, MD 1 ABSTRACT Antibody-based immunotherapeutic agents have emerged as important
More informationHow to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma
How to incorporate new therapies into the treatment algorithm of patients with mantle cell lymphoma Dr. Guillermo Rodríguez García Hospital Universitario Virgen Macarena Hospital Universitario Virgen del
More informationMonoclonal Antibody Therapy in Lymphoid Malignancies. The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
The Oncologist Promising New Drugs and Combinations Monoclonal Antibody Therapy in Lymphoid Malignancies JOHN D. HAINSWORTH The Sarah Cannon Cancer Center, Centennial Medical Center, Nashville, Tennessee,
More informationFollicular lymphoma (FL) is one the most frequent
Malignant Lymphomas Decision Making and Problem Solving Current status and perspective of antibody therapy in follicular lymphoma Christian Buske Oliver Weigert Martin Dreyling Michael Unterhalt Wolfgang
More informationMathias J Rummel, MD, PhD
I N T E R V I E W Mathias J Rummel, MD, PhD Prof Rummel is Head of the Department of Hematology at the Hospital of the Justus-Liebig University in Gießen, Germany. Tracks 1-17 Track 1 Track 2 Track 3 Track
More informationRituximab in lymphoma: A systematic review and consensus practice guideline from Cancer Care Ontario
Cancer Treatment Reviews (2007) 33, 161 176 available at www.sciencedirect.com journal homepage: www.elsevierhealth.com/journals/ctrv ANTI-TUMOUR TREATMENT Rituximab in lymphoma: A systematic review and
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationMantle Cell Lymphoma: Update in Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency
Mantle Cell Lymphoma: Update in 2015 Diego Villa, MD MPH FRCPC Medical Oncologist BC Cancer Agency Disclosures Research funding: Roche provides research funding to support the Centre for Lymphoid Cancer
More informationOriginal Articles ABSTRACT. Acknowledgments: we thank all
Original Articles Impact of the use of autologous stem cell transplantation at first relapse both in naïve and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000
More informationThis tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to:
This tutorial gives an overview of Radioimmunotherapy in Non-Hodgkin s Lymphoma. After completing this tutorial, attendees will be able to: Name the radiopharmaceutical approved by the FDA for performance
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationRituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab for the first-line treatment of stage III-IV (review of guidance 110) Issued: January 2012 guidance.nice.org.uk/ta243 NICE has accredited the process used by the Centre for Health Technology
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationResults of a Prospective Randomized Trial of the German Low-Grade Lymphoma Study Group
1014 Combined Cyclophosphamide, Vincristine, Doxorubicin, and Prednisone (CHOP) Improves Response Rates but Not Survival and Has Lower Hematologic Toxicity Compared With Combined Mitoxantrone, Chlorambucil,
More informationManaging patients with relapsed follicular lymphoma. Case
Managing patients with relapsed follicular lymphoma John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine Associate Director, Weill Cornell
More informationNCCN Non Hodgkin s Lymphomas Guidelines V Update Meeting 06/14/12 and 06/15/12
NCCN Non Hodgkin s Lymphomas Guidelines V.1.213 Update Meeting 6/14/12 and 6/15/12 Guidelines Page and Request Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL) Panel Discussion References
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationThessaloniki, Greece PLEASE SCROLL DOWN FOR ARTICLE
This article was downloaded by:[heal-link Consortium] On: 27 July 2008 Access Details: [subscription number 772810551] Publisher: Informa Healthcare Informa Ltd Registered in England and Wales Registered
More informationIbritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline
Evidence-based Series #6-17: Section 1 Ibritumomab Tiuxetan in Lymphoma: A Clinical Practice Guideline M. Cheung, A.E. Haynes, A. Stevens, R.M. Meyer, K. Imrie, and the members of the Hematology Disease
More informationlandmarks Lymphoma STUDY SUMMARY: Immediate use of rituximab may change standard of care
Lymphoma Improving Time to Initiation of New Therapy Douglas Stewart, MD, FRCPC, Chief, Division of Hematology & Hematologic Malignancies, University of Calgary; Provincial Leader, Hematology Tumour Team,
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages)
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170029P 1 NHS England INFORMATION READER BOX Directorate Medical
More information148 P&T March 2010 Vol. 35 No. 3
Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin s Lymphoma Efrat Dotan, MD, Charu Aggarwal, MD, MPH, and Mitchell R. Smith, MD, PhD ABSTRACT Non-Hodgkin s lymphoma (NHL) is the most
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationAn overview of the current clinical use of the anti-cd20 monoclonal antibody rituximab
Review Annals of Oncology 14: 520 535, 2003 DOI: 10.1093/annonc/mdg175 An overview of the current clinical use of the anti-cd20 monoclonal antibody rituximab J. Boye, T. Elter & A. Engert* Clinic I of
More informationAn overview of the current clinical use of the anti-cd20 monoclonal antibody rituximab
Review Annals of Oncology 14: 520 535, 2003 DOI: 10.1093/annonc/mdg175 An overview of the current clinical use of the anti-cd20 monoclonal antibody rituximab J. Boye, T. Elter & A. Engert* Clinic I of
More informationIndividualized management of follicular lymphoma
Review Article Page 1 of 14 Individualized management of follicular lymphoma Bing Bai 1,2, Hui-Qiang Huang 1,2 1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationeastern cooperative oncology group Michael Williams, Fangxin Hong, Brad Kahl, Randy Gascoyne, Lynne Wagner, John Krauss, Sandra Horning
Results of E4402 (RESORT): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Indolent B-Cell Lymphoma Michael Williams, Fangxin Hong, Brad Kahl, Randy
More informationRadioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms
Review Nuclear Medicine Review 2007 Vol. 10, No. 2, pp. 110 115 Copyright 2007 Via Medica ISSN 1506 9680 Radioimmunotherapy for lymphoma analysis of clinical trials and treatment algorithms Wojciech Jurczak
More informationBlood Cancers. Blood Cells. Blood Cancers: Progress and Promise. Bone Marrow and Blood. Lymph Nodes and Spleen
Blood Cancers: Progress and Promise Mike Barnett & Khaled Ramadan Division of Hematology Department of Medicine Providence Health Care & UBC Blood Cancers Significant health problem Arise from normal cells
More informationCLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE
FOR IMMEDIATE RELEASE CLINICAL RESEARCH RESULTS FROM THE ANNUAL MEETINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY AND THE SOCIETY OF NUCLEAR MEDICINE Results of Studies of BEXXAR TM Therapy Show Promise
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationManaging Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options
Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options Fernando Cabanillas (Chair), Sandra Horning, Mark Kaminski, and Richard Champlin The front-line management of stage
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationOverview. Table of Contents. A Canadian perspective provided by Isabelle Bence-Bruckler, MD, FRCPC
2 A C A N A D I A N P E R S P E C T I V E Volume 2 November 2005 Overview The International Conference on Malignant Lymphoma (ICML) is held every three years in Lugano, Switzerland. ICML started nearly
More information7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia
1 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom and Related Disorders Conditions: Multiple Myeloma; Waldenstrom's ; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma Intervention:
More informationTHE USE OF IBRITUMOMAB AS CONSOLIDATION THERAPY AFTER REMISSION INDUCTION IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
THE USE OF IBRITUMOMAB AS CONSOLIDATION THERAPY AFTER REMISSION INDUCTION IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA Wolfson Unit Claremont Place Newcastle upon Tyne NE2 4HH May 2009 n THE USE OF IBRITUMOMAB
More informationNon-Hodgkin s Lymphoma
Non-Hodgkin s Lympoma Non-Hodgkin s Lymphomas Janet H. Van Cleave MSN, ACNP-CS, CS, AOCN Acute Care Nurse Practitioner The Mount Sinai Medical Center of New York City Doctoral Student, Yale University
More informationIndium-111 Zevalin Imaging
Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.
More informationRole of antibody therapy in lymphoid malignancies
Role of antibody therapy in lymphoid malignancies Claire E. Dearden * The Royal Marsden Hospital and Institute of Cancer Research, London, UK Introduction Accepted: August 26, 2007 *Correspondence to:
More informationScottish Medicines Consortium
Scottish Medicines Consortium rituximab 10mg/ml concentrate for infusion (MabThera ) Roche (No.330/06) 10 November 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationChallenges in the Treatment of Follicular Lymphoma
Challenges in the Treatment of Follicular Lymphoma Prof. Michele Ghielmini Clinical Director Oncology Institute of Southern Switzerland Bellinzona ESMO guidelines 2014 (simplified) Low tumor burden High
More informationMARIO PETRINI Ematologia PISA UO Ematologia - Pisa
I LINFOMI NON HODGKIN A BASSO GRADO DI MALIGNITA PESCARA 2008 linfomi mantellari MARIO PETRINI Ematologia PISA Mantle Cell Lymphoma Typical (Classic) small to medium-sized Ly with scanty cytoplasm, irregular
More informationClinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: P
Clinical Commissioning Policy: Bendamustine with rituximab for relapsed and refractory mantle cell lymphoma (all ages) NHS England Reference: 170054P 1 NHS England INFORMATION READER BOX Directorate Medical
More informationThe Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States
The Use and Effectiveness of Rituximab Maintenance in Patients with Follicular Lymphoma Diagnosed Between 2004 and 2007 in the United States Loretta J Nastoupil, The University of Texas MD Anderson Cancer
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationRituximab maintenance therapy of follicular lymphoma in clinical practice
Received: 20 December 2017 Revised: 10 April 2018 DOI: 10.1002/cam4.1549 Accepted: 19 April 2018 ORIGINAL RESEARCH Rituximab maintenance therapy of follicular lymphoma in clinical practice Ulrich Dührsen
More informationLondon Cancer New Drugs Group APC/DTC Briefing
London Cancer New Drugs Group APC/DTC Briefing Rituximab for Mantle Cell Lymphoma g Contents Summary Summary & Background 1-2 Introduction 3 Discussion points/issues for Consideration 9 References 12 Background
More informationMonoclonal Antibodies in Advanced B- cell Lymphomas
Monoclonal Antibodies in Advanced B- cell Lymphomas By Chaitra Ujjani, MD Bruce D. Cheson, MD Georgetown University Hospital Lombardi Comprehensive Cancer Center Washington, DC February 9, 2010 Financial
More informationTRANSPARENCY COMMITTEE OPINION. 27 January 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 January 2010 TORISEL 25 mg/ml, concentrate for solution and diluent for solution for infusion Box containing 1
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationFollicular Lymphoma 2016:
Follicular Lymphoma 2016: Evolving Management Strategies Randeep Sangha, MD Medical Oncology, Cross Cancer Institute Associate Professor, University of Alberta Edmonton, AB Disclosures I have no actual
More informationTraditional Therapies for Waldenstrom s Macroglobulinemia. Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014
Traditional Therapies for Waldenstrom s Macroglobulinemia Christine Chen Princess Margaret Cancer Centre Toronto, Canada May 2014 Jeff Atlin (1953-2014) Standard treatment options Single drug therapies
More informationNon-Hodgkin lymphomas (NHLs) constitute a heterogeneous. Original Articles
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS Volume 28, Number 5, 2013 ª Mary Ann Liebert, Inc. DOI: 10.1089/cbr.2012.1387 Original Articles Phase I Study of a Modified Regimen of 90 Yttrium Ibritumomab
More informationCurrent and future management of follicular lymphoma
Int J Hematol (2012) 96:544 551 DOI 10.1007/s12185-012-1202-y PROGRESS IN HEMATOLOGY Current and Future Management of Major Subtypes of Malignant Lymphoma Based on Clinical Trials Current and future management
More informationMarked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.
Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry. Abrahamsson, Anna; Dahle, Nina; Jerkeman, Mats Published in: Leukemia & lymphoma
More informationJ Clin Oncol 26: by American Society of Clinical Oncology INTRODUCTION
VOLUME 26 NUMBER 2 JANUARY 10 2008 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin s Lymphoma: Results From
More information